Our markets

We are an international pharmaceutical company. Our headquarters are based in Italy, where we are deeply rooted as one of the leading companies in primary care.
Thanks to our subsidiaries around the world and several top distributors, we distribute our products in more than 100 countries, with a global turnover in 2023 of approximately 1.4 billions euro.
Half of this turnover is a result of our proprietary molecules, designed and developed in our R&D centers (Rifaximin, Sulodexide, Carnitine, L-methylfolate, Parnaparin).
Our second market is the US. After the acquisition of Pamlab in 2016, we now have a strong hold in the nutraceuticals and medical food sectors.
Russia, Spain, Romania, China, Poland, France and Mexico are our other main markets.